It would be interesting to investigate whether an increased efficacy of chemo- and radiotherapy and a reduced lung cancer cell resistance may arise from dual pharmacological targeting of NRF2 and NOTCH pathways, so as to represent a promising therapeutic strategy in preclinical and clinical studies [8,9]. This evidence concerns the gene NFE2L2 and lung carcinoma.